Background-Whether mitral valve repair during coronary artery bypass grafting (CABG) improves survival in patients with ischemic mitral regurgitation (MR) remains unknown. Methods and Results-Patients with ejection fraction Յ35% and coronary artery disease amenable to CABG were randomized at 99 sites worldwide to medical therapy with or without CABG. The decision to treat the mitral valve during CABG was left to the surgeon. The primary end point was mortality. Of 1212 randomized patients, 435 (36%) had none/trace MR, 554 (46%) had mild MR, 181 (15%) had moderate MR, and 39 (3%) had severe MR. In the medical arm, 70 deaths (32%) occurred in patients with none/trace MR, 114 (44%) in those with mild MR, and 58 (50%) in those with moderate to severe MR. In patients with moderate to severe MR, there were 29 deaths (53%) among 55 patients randomized to CABG who did not receive mitral surgery (hazard ratio versus medical therapy, 1.20; 95% confidence interval, 0.77-1.87) and 21 deaths (43%) among 49 patients who received mitral surgery (hazard ratio versus medical therapy, 0.62; 95% confidence interval, 0.35-1.08). After adjustment for baseline prognostic variables, the hazard ratio for CABG with mitral surgery versus CABG alone was 0.41 (95% confidence interval, 0.22-0.77; Pϭ0.006). Conclusion-Although these observational data suggest that adding mitral valve repair to CABG in patients with left ventricular dysfunction and moderate to severe MR may improve survival compared with CABG alone or medical therapy alone, a prospective randomized trial is necessary to confirm the validity of these observations. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595. Key Words: cardiomyopathy Ⅲ coronary disease Ⅲ mitral valve Ⅲ surgery Ⅲ trials C hronic ischemic mitral regurgitation (MR) is associated with heart failure and increased mortality. [1][2][3] The severity of ischemic MR adversely affects survival after percutaneous or surgical myocardial revascularization. 4 -6 The optimal treatment strategy for ischemic MR remains controversial. European practice guidelines recommend mitral valve repair (MVRep) in patients with severe or even moderate ischemic MR and an ejection fraction (EF) Ͼ30% who are undergoing coronary artery bypass grafting (CABG). 7 However, retrospective analyses using propensity score matching showed no survival benefit of adding MVRep to CABG. 8 -10 The need to add MVRep in patients with an indication for CABG becomes even less clear when MR is less severe and left ventricular (LV) dysfunction is more severe. Few data exist comparing surgical and medical management of patients with significant ischemic MR. 10 To address this major knowledge gap in our understanding of ischemic MR, we analyzed the impact of MR on survival in the recently reported Surgical Treatment for Ischemic Heart Failure (STICH) trial. 11
C hronic ischemic mitral regurgitation (MR) is associated with heart failure and increased mortality. [1] [2] [3] The severity of ischemic MR adversely affects survival after percutaneous or surgical myocardial revascularization. 4 -6 The optimal treatment strategy for ischemic MR remains controversial. European practice guidelines recommend mitral valve repair (MVRep) in patients with severe or even moderate ischemic MR and an ejection fraction (EF) Ͼ30% who are undergoing coronary artery bypass grafting (CABG). 7 However, retrospective analyses using propensity score matching showed no survival benefit of adding MVRep to CABG. 8 -10 The need to add MVRep in patients with an indication for CABG becomes even less clear when MR is less severe and left ventricular (LV) dysfunction is more severe. Few data exist comparing surgical and medical management of patients with significant ischemic MR. 10 To address this major knowledge gap in our understanding of ischemic MR, we analyzed the impact of MR on survival in the recently reported Surgical Treatment for Ischemic Heart Failure (STICH) trial. 11 
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This report focuses on the 1212 STICH hypothesis 1 patients randomized to CABG (nϭ610) or medical therapy (MED; nϭ602). Among patients undergoing CABG, the decision to repair or not repair the mitral insufficiency was not randomized. However, because every patient had to be eligible for MED alone, the MED cohort provides a unique control group whose subsequent survival on MED alone can be compared with that of CABG patients with similar magnitudes of MR for whom MVRep was an option but not required.
In this report, we evaluate the prognostic influence of baseline MR severity in patients enrolled in STICH, compare the survival of patients with various degrees of MR severity by treatment assignment to MED or CABG, and compare survival among patients with moderate to severe MR who did or did not receive MVRep at the time of CABG versus those assigned to MED.
Methods
The design, protocol, and primary outcome of the STICH trial have been reported. 11, 12 This multicenter nonblinded study randomized 1212 patients at 99 medical centers in 22 countries over 4.8 years. 13 Eligible patients had coronary artery disease amenable to CABG and LVEF Յ35%. Major exclusion criteria included significant (Ͼ50%) left main disease and/or Canadian Cardiovascular Society Class 3 or 4 angina, recent acute myocardial infarction, hemodynamic instability, planned percutaneous revascularization, or aortic valvular surgery. Patients were randomly (1:1) assigned to intensive MED alone or to CABG in addition to MED.
Patients with all grades of MR could be randomized to MED with or without CABG. In patients assigned to CABG, the decision to perform adjunctive mitral surgery was left to the clinical judgment of the surgeon. The 50% chance of a MED assignment created a cohort for whom a definite need for CABG with MVRep was not apparent at the time of randomization.
The baseline case report form permitted the baseline MR grade to be characterized by the site study investigators as none or trace, mild, moderate, severe, or not assessed. The STICH trial cardiovascular imaging core laboratories were staffed by investigators blinded to the randomized treatment. However, the core laboratory assessments of MR were not available to the study surgeon at the time of randomization and could not have influenced the MVRep decision in patients randomized to CABG. Therefore, we elected to use the site-reported assessment of MR severity to group patients for analysis.
All STICH surgeons were certified by the STICH Surgical Committee as having had performed at least 25 CABGs on patients with an EF Ͻ40% with operative mortality Ͻ5%. Medical therapy was optimized under the guidance of the lead cardiologist at each site. Patients were followed up at 30 days (or at discharge, whichever occurred earlier), at 4-month intervals during the first year, and every 6 months thereafter.
Statistical Analysis
Baseline patient characteristics and details of the CABG surgery and perioperative course were summarized by use of the medians and quartiles for continuous variables and frequencies and percentages for categorical variables. Group comparisons of continuous and ordinal variables were performed with nonparametric procedures (Wilcoxon rank-sum test for 2-group comparisons and KruskalWallis ANOVA for 3-group comparisons). Categorical factors were compared by use of the 2 test or Fisher exact test. Cumulative mortality rates were calculated with the Kaplan-Meier method. 14 All death or censoring times were measured from the time of randomization. The significance of mortality differences between patient groups was assessed with the Cox regression model. 15 The Cox model provided relative risks, expressed as hazard ratios (HRs) with associated 95% confidence intervals (CIs).
Mortality comparisons of the randomized treatment arms were performed according to the intention-to-treat principle. Because mitral valve surgery could be added only in those patients assigned to CABG who actually underwent the treatment assigned, the per-protocol analysis of mortality in the group of patients with moderate to severe MR excluded patients who did not receive their assigned treatment within a year after randomization. All other per-protocol analyses are presented in the online-only Data Supplement.
A propensity analysis among patients with moderate or severe MR treated with CABG performed with logistic multiple regression identified baseline factors associated with subsequent performance of mitral valve surgery. The long-term mortality of the patients with moderate or severe MR undergoing CABG with versus without mitral valve surgery was compared by use of the Cox model with adjustment for key baseline factors to minimize the possible effects of confounding. The adjustment variables included enrollment region, age, LVEF, number of diseased vessels, New York Heart Association heart failure class, diabetes mellitus, and 6-minute walk distance. Patients unable to perform the walk test were assigned a walk distance of zero.
Results

Study Population
Between July 24, 2002 , and May 5, 2007 , 1212 patients were enrolled in the STICH hypothesis 1 trial. MR was not assessed in 3 patients. Tables 1 and 2 summarize the baseline characteristics of the 1209 patients with severity of MR reported as none or trace in 435 (36%), mild in 554 (46%), moderate in 181 (15%), and severe in 39 (3%). Increasing MR grade was associated with larger LV end-systolic volume index, lower LVEF, higher New York Heart Association class, shorter 6-minute walk distance, and higher risk at randomization score (calculated from a model previously developed with the Duke Cardiovascular Database Registry 13 ; Table 1 ). Although enrollment was not stratified on MR severity, baseline characteristics of medically and surgically treated patients were well balanced at each level of MR (Table 2) .
Among 104 patients assigned to CABG with site-reported moderate to severe MR, 91 underwent CABG and 49 received an adjunctive concomitant mitral valve procedure (48 repairs and 1 bioprosthesis implantation). Patients who received mitral valve surgery had significantly lower LVEF, larger LV end-systolic volume index, and longer distance on the 6-minute walk test (Table 3 ). The extent of coronary artery disease was similar in both groups. Diabetes mellitus was more prevalent in those receiving CABG alone. The estimated risk at randomization was similar in both groups. Propensity modeling showed lower LVEF (PϽ0.001) and enrollment in Europe (PϽ0.001) to relate most strongly to receiving MVRep with CABG.
Operative Procedure
MR grade did not influence coronary revascularization conduct. A median of 3 grafts were done per patient, and 90% of patients received at least 1 arterial graft (Table 4) . The proportion of patients with MVRep increased with MR grade. *The risk at randomization was estimated from a model previously developed with data from the Duke Cardiovascular Database Registry. 13 formed without cardiopulmonary bypass. Cross-clamp time, cardiopulmonary bypass time, and the duration of procedure were all longer in patients who had a concomitant MVRep compared with CABG-only patients.
Postoperative Course
Patients with moderate to severe MR spent more time in the intensive care unit and required more hemodynamic support with inotropes (34% versus 38% versus 52%, none or trace Chronic renal disease, n (%) 15 (7) 20 (9) 18 (7) 20 (7) 12 (10) 9 (9) Previous stroke, n (%) 12 (5) 22 (10) 20 (8) 20 (7) 9 (8) 9 (9) Previous PCI, n (%) 22 (10) 27 (13) 32 (12) 34 (12) 20 (17) 21 (20) Previous CABG, n (%)
Current CCS angina class, n (%) 
Highest NYHA class in last 3 mo, n (%) I 17 (8) 12 (6) 16 (6) 14 (5) (Table 5) .
Adherence to guideline-based use of medication was high in all treatment cohorts throughout the study period (Tables  III and IV 
Survival
Follow-up for death was complete at a median of 56 months in the 1209 patients with baseline MR grade reported. In the 599 patients randomized to MED alone, mortality was strongly related to MR severity at baseline (Figure 1 ). There were 70 deaths in 222 patients (32%) with none or trace MR, 114 in 261 patients (44%) with mild MR (HR versus no MR, 1.54; 95% CI, 1.14 -2.07), and 58 in 116 patients (50%) with moderate to severe MR (HR versus no MR, 2.01; 95% CI, 1.42-2.85). Figure 2B ). This difference was significant in per-protocol analysis of this subgroup ( Figure IIB in the online-only Data Supplement). Death occurred in 50 of 104 patients (48%) with moderate to severe MR assigned to CABG (HR versus MED, 0.92; 95% CI, 0.63-1.35; Figure 2C ).
There were 29 deaths in the 55 CABG-assigned patients (53%) who did not receive a mitral procedure (HR versus MED, 1.20; 95% CI, 0.77-1.87) and 21 deaths in 49 patients (43%) who received mitral surgery added to CABG (HR versus MED, 0.68; 95% CI, 0.41-1.12; Figure 3 ). There was A per-protocol analysis of mortality in patients with moderate to severe MR excluded the 12 patients (10%) assigned to MED who received CABG within a year of randomization and the 13 patients (13%) assigned to CABG who did not undergo surgery. Of 104 patients with moderate to severe MR assigned to MED and treated medically, 53 (51%) died. This compares to 22 deaths (52%) observed in 42 patients assigned to CABG and treated with CABG alone (HR versus MED, 1. 
Discussion
The STICH trial results are consistent with observational studies demonstrating that even mild MR is associated with decreased survival in medically treated patients with ischemic cardiomyopathy. 2, 3, 16 We report outcomes of an intraoperative decision to perform or not perform mitral valve surgery among ischemic cardiomyopathy patients randomized to a surgical versus medical strategy of care. Trichon et al 10 also reported an observational comparison of surgical versus medical therapy in prospectively defined ischemic MR cohorts using data from the Duke Databank for Cardiovascular Diseases. After propensity adjustment, survival benefit was 17 Other reports found that repair of ischemic MR at the time of CABG did not significantly increase perioperative mortality. Mortality was reported to be 4% in both groups by Diodato et al, 8 3.5% versus 1.8% by Goland et al, 18 or 4.1% versus 1.8% by Fattouch et al 19 In the report by Mihaljevic et al, 9 hospital mortality was twice as high in the CABG-only group compared with the CABG with MVRep (7.4% versus 3.7%; PϭNS). Still, no long-term survival benefit of performing MVRep was demonstrated.
Our results differ from many reports that suggest adding MVRep to CABG increases early risk without adding longterm survival benefit. 19 -21 STICH patients with an MVRep added to CABG had a more complicated early postoperative period. The duration of intensive care unit stay was nearly doubled, and more balloon pumps and inotropes were used postoperatively. Postoperative infections were common, and 10% of CABG patients with an added MVRep were still in the hospital 30 days postoperatively. Despite greater morbidity from adding MVRep to CABG, 6 of the 7 perioperative deaths in surgically treated patients with moderate to severe MR occurred in those treated with CABG only. This suggests that there may also be harm from failure to address moderate to severe MR in patients undergoing CABG. Additional observations in larger numbers of patients undergoing CABG with moderate to severe MR are needed to confirm whether failure to repair moderate to severe MR in patients undergoing CABG decreases long-term survival.
Compared with other reports of operative treatment of moderate to severe ischemic MR, STICH patients had lower EF, less angina, and more heart failure and were selected because of clinical equipoise for the need for CABG. Although STICH data suggest that MVRep should be considered among STICH-like patients with moderate to severe MR undergoing CABG, our data do not support using the presence of moderate to severe MR as the primary indication for CABG. Additionally, the high 5-year mortality regardless of therapy indicates that in these patients alternative approaches, including heart transplantation and LV assist devices, should also be considered.
Limitations
Our report is limited by the small number of patients in the moderate to severe MR cohort and the lack of a secondary randomization to MVRep. However, our study reports outcomes observed in a very well-defined and prospectively followed up group of patients in whom the decision to receive surgical treatment was randomized. Many confounding factors could influence the operative decision to perform or not perform MVRep. We cannot exclude the possibility that surgeons were more reluctant to perform a mitral procedure in less healthy patients. A tendency for STICH surgeons to perform CABG alone in higher-risk patients and to add a mitral procedure to CABG in lower-risk patients might diminish survival in the CABG-only cohort and enhance survival in the CABGϩMVRep group with an intermediate outcome in those randomized to MED. Indeed, we noted more diabetes mellitus among the patients in whom surgeons decided not to treat the mitral valve. On the other hand, the risk at randomization index was similar in both groups. The patients subjected to MVRep had larger left ventricles on average and lower EFs. It appears that the main factor related to surgeon's decision was the region of the world where the patient was enrolled. Moreover, statistical adjustment for baseline characteristics of STICH patients actually accentuated the survival advantage of CABGϩMVRep over CABG alone. Still, there are factors that could not be adjusted for in multivariable modeling. Information on surgical intraoperative decision making relative to MVRep was not collected, and the potential for confounding based on operative conduct exists. Although 40% of the CABG-only procedures were performed off pump, suggesting preoperative decisions against mitral valve surgery, intraoperative events cannot be excluded as a source of bias against CABG without MVRep.
Bearing all of these limitations in mind, we believe that these STICH patients are a uniquely valuable prospectively defined observational cohort typical of patients in whom some cardiac surgeons would and other cardiac surgeons would not repair the mitral valve.
Moreover, despite not randomizing the MVRep decision, the 2 surgical groups in patients with moderate or severe baseline MR have similar numbers of patients with quite comparable baseline characteristics, risk at randomization index, and quality of revascularization. Our report provides the only prospectively defined survival comparison of adding MVRep to CABG in patients who were all defined as eligible for CABG but half of whom did not receive CABG by random assignment. The only other randomized comparison on this topic in the literature deals with patients with clear indications for CABG and minimal LV dysfunction. 18 An ongoing Cardiothoracic Surgical Trials Network trial is now randomizing patients with moderate MR and a primary indication for CABG to MVRep versus no repair. This trial is powered for a primary end point of reduction in LV end-systolic volume index, not mortality. 22 Our data support the need for a randomized trial of medical versus surgical therapy involving CABG with MVRep in patients with low EF resulting from ischemic cardiomyopathy and at least moderate MR that would address survival as a primary end point. Our data also provide valuable survival information needed for estimating the cohort size necessary for a definitive trial. Executing such a trial is likely to be very challenging, however. A trial in which patients with moderate to severe MR before CABG are randomized to undergo or not undergo MVRep has a high likelihood of being affected by a sizable number of intraoperative crossovers. Randomizing patients with a significant degree of MR to medical therapy may be even more difficult, as evidenced by the small percentage of patients with moderate to severe MR who were included in the STICH trial. Thus, this study may remain for a long time as the only comparison that has a well-defined medical cohort as a comparator group.
Use of clinical site-reported MR severity rather than that reported by the STICH echocardiography core laboratory may be viewed as a limitation or a strength of this report. The core laboratory result was a single time point reading not available to the operating surgeon. MR often varies with exercise, blood volume status, and afterload. 23, 24 Many cardiac surgeons insist that an operative decision for MR should not be based on a single echocardiography reading, particularly only an intraoperative one. 25 The influence of the preoperative grading of MR on subsequent 5-year survival in both the medical and surgical randomized cohorts demonstrates site-reported MR severity to be strongly related to survival in medically and surgically treated patients.
These observational data from the STICH trial indicate that adding MVRep to CABG in patients with LV dysfunction and moderate to severe MR may improve survival compared with CABG alone or MED alone. However, because of possible confounding by indication, a prospective randomized trial to confirm the validity of these observations is justified.
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CLINICAL PERSPECTIVE
Chronic ischemic mitral regurgitation (MR) is associated with heart failure and increased mortality. The optimal treatment strategy for ischemic MR remains controversial. European practice guidelines recommend mitral valve repair in patients with severe or even moderate ischemic MR and an ejection fraction Ͼ30% who are undergoing coronary artery bypass grafting (CABG), even though retrospective analyses using propensity score matching showed no survival benefit of adding mitral valve repair to CABG. The need to add mitral valve repair in patients with an indication for CABG becomes even less clear when left ventricular dysfunction is more severe. The Surgical Treatment for Ischemic Heart Failure (STICH) trial randomized 1212 patients with severe left ventricular dysfunction (ejection fraction Ͻ35%) and coronary artery disease amenable to CABG to intensive medical therapy alone or in association with CABG. The decision to repair the mitral valve was left to the operating surgeon. Survival in the medically treated cohort depended strongly on MR grade at baseline, with mortality hazard being increased twice in patients with moderate to severe MR compared with patients with no MR. In patients with mild MR, CABG was associated with improved survival. In patients with moderate to severe MR, adding mitral valve repair to CABG tended to improve survival compared with CABG alone or medical therapy alone. Unfortunately, the decision to repair the valve was not randomized; therefore, even though risk adjustment actually accentuated the difference of survival in favor of adding mitral valve repair, a randomized trial is required to confirm our findings.
Influence of Mitral Regurgitation Repair on Survival In the Surgical Treatment for
Ischemic Heart Failure Trial -SUPPLEMENTAL MATERIAL MA Deja et al.
Supplemental Methods
This supplement contains the per-protocol mortality analyses.
Also, baseline treatment of patients with moderate-severe MR is presented. 
Supplemental Results
Study population
Outcome
Mortality in the patients assigned to MED and treated medically was strongly related to MR severity at baseline (Figure 1 ). Although mortality tended to be lower with surgical treatment at every level of MR, this was only statistically significant in patients with mild MR (Figure 2 
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C
hronic ischemic mitral regurgitation (MR) is associated with heart failure and increased mortality. [1] [2] [3] The severity of ischemic MR adversely affects survival after percutaneous or surgical myocardial revascularization. [4] [5] [6] The optimal treatment strategy for ischemic MR remains controversial. European practice guidelines recommend mitral valve repair (MVRep) in patients with severe or even moderate ischemic MR and an ejection fraction (EF) �30% who are undergoing coronary artery bypass grafting (CABG). 7 However, retrospective analyses using propensity score matching showed no survival benefit of adding MVRep to CABG. 8 -10 The need to add MVRep in patients with an indication for CABG becomes even less clear when MR is less severe and left ventricular (LV) dysfunction is more severe. Few data exist comparing surgical and medical management of patients with significant ischemic MR. 10 To address this major knowledge gap in our understanding of ischemic MR, we analyzed the impact of MR on survival in the recently reported Surgical Treatment for Ischemic Heart Failure (STICH) trial. 11
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This report focuses on the 1212 STICH hypothesis 1 patients randomized to CABG (n�610) or medical therapy (MED; n�602). Among patients undergoing CABG, the decision to repair or not repair the mitral insufficiency was not randomized. However, because every patient had to be eligible for MED alone, the MED cohort provides a unique control group whose subsequent survival on MED alone can be compared with that of CABG patients with similar magnitudes of MR for whom MVRep was an option but not required.
Methods
The design, protocol, and primary outcome of the STICH trial have been reported. 11, 12 This multicenter nonblinded study randomized 1212 patients at 99 medical centers in 22 countries over 4.8 years. 13 Eligible patients had coronary artery disease amenable to CABG and LVEF �35%. Major exclusion criteria included significant (�50%) left main disease and/or Canadian Cardiovascular Society Class 3 or 4 angina, recent acute myocardial infarction, hemodynamic instability, planned percutaneous revascularization, or aortic valvular surgery. Patients were randomly (1:1) assigned to intensive MED alone or to CABG in addition to MED.
All STICH surgeons were certified by the STICH Surgical Committee as having had performed at least 25 CABGs on patients with an EF �40% with operative mortality �5%. Medical therapy was optimized under the guidance of the lead cardiologist at each site. Patients were followed up at 30 days (or at discharge, whichever occurred earlier), at 4-month intervals during the first year, and every 6 months thereafter.
Statistical Analysis
Baseline patient characteristics and details of the CABG surgery and perioperative course were summarized by use of the medians and quartiles for continuous variables and frequencies and percentages for categorical variables. Group comparisons of continuous and ordinal variables were performed with nonparametric procedures (Wilcoxon rank-sum test for 2-group comparisons and KruskalWallis ANOVA for 3-group comparisons). Categorical factors were compared by use of the � 2 test or Fisher exact test. Cumulative mortality rates were calculated with the Kaplan-Meier method. 14 All death or censoring times were measured from the time of randomization. The significance of mortality differences between patient groups was assessed with the Cox regression model. 15 The Cox model provided relative risks, expressed as hazard ratios (HRs) with associated 95% confidence intervals (CIs).
Results
Study Population
Between July 24, 2002, and May 5, 2007, 1212 patients were enrolled in the STICH hypothesis 1 trial. MR was not assessed in 3 patients. Tables 1 and 2 summarize the baseline characteristics of the 1209 patients with severity of MR reported as none or trace in 435 (36%), mild in 554 (46%), moderate in 181 (15%), and severe in 39 (3%). Increasing MR grade was associated with larger LV end-systolic volume index, lower LVEF, higher New York Heart Association class, shorter 6-minute walk distance, and higher risk at randomization score (calculated from a model previously developed with the Duke Cardiovascular Database Registry 13 ; Table 1 ). Although enrollment was not stratified on MR severity, baseline characteristics of medically and surgically treated patients were well balanced at each level of MR (Table 2) .
Among 104 patients assigned to CABG with site-reported moderate to severe MR, 91 underwent CABG and 49 received an adjunctive concomitant mitral valve procedure (48 repairs and 1 bioprosthesis implantation). Patients who received mitral valve surgery had significantly lower LVEF, larger LV end-systolic volume index, and longer distance on the 6-minute walk test (Table 3 ). The extent of coronary artery disease was similar in both groups. Diabetes mellitus was more prevalent in those receiving CABG alone. The estimated risk at randomization was similar in both groups. Propensity modeling showed lower LVEF (P�0.001) and enrollment in Europe (P�0.001) to relate most strongly to receiving MVRep with CABG.
Operative Procedure
MR grade did not influence coronary revascularization conduct. A median of 3 grafts were done per patient, and 90% of patients received at least 1 arterial graft (Table 4) . The proportion of patients with MVRep increased with MR grade. Chronic renal disease, n (%) 35 (8) 38 (7) 21 (10) 0.442
Previous stroke, n (%) 34 (8) 40 (7) 18 (8) 0.883
Previous PCI, n (%) 49 (11) 66 (12) 41 (19) 0.019
Previous CABG, n (%) 11 (3) 13 (2) 11 (5) (4) 18 (3) 13 (6) 4 3 (1) 4 (1) 3 (1) Highest NYHA class in last 3 mo, n (%)
�0.001
I 29 (7) 30 (5) 10 (5 (Table 5) .
Adherence to guideline-based use of medication was high in all treatment cohorts throughout the study period (Tables  III and IV in 
Survival
There were 29 deaths in the 55 CABG-assigned patients (53%) who did not receive a mitral procedure (HR versus MED, 1.20; 95% CI, 0.77-1.87) and 21 deaths in 49 patients (43%) who received mitral surgery added to CABG (HR versus MED, 0.68; 95% CI, 0.41-1.12; Figure 3 ). There was 
Discussion
The STICH trial results are consistent with observational studies demonstrating that even mild MR is associated with decreased survival in medically treated patients with ischemic cardiomyopathy. 2, 3, 16 We report outcomes of an intraoperative decision to perform or not perform mitral valve surgery among ischemic cardiomyopathy patients randomized to a surgical versus medical strategy of care. Trichon et al 10 also reported an observational comparison of surgical versus medical therapy in prospectively defined ischemic MR cohorts using data from the Duke Databank for Cardiovascular Diseases. After propensity adjustment, survival benefit was 17 Other reports found that repair of ischemic MR at the time of CABG did not significantly increase perioperative mortality. Mortality was reported to be 4% in both groups by Diodato et al, 8 3.5% versus 1.8% by Goland et al, 18 or 4.1% versus 1.8% by Fattouch et al 19 In the report by Mihaljevic et al, 9 hospital mortality was twice as high in the CABG-only group compared with the CABG with MVRep (7.4% versus 3.7%; P�NS). Still, no long-term survival benefit of performing MVRep was demonstrated.
Limitations
Our report is limited by the small number of patients in the moderate to severe MR cohort and the lack of a secondary randomization to MVRep. However, our study reports outcomes observed in a very well-defined and prospectively followed up group of patients in whom the decision to receive surgical treatment was randomized. Many confounding factors could influence the operative decision to perform or not perform MVRep. We cannot exclude the possibility that surgeons were more reluctant to perform a mitral procedure in less healthy patients. A tendency for STICH surgeons to perform CABG alone in higher-risk patients and to add a mitral procedure to CABG in lower-risk patients might diminish survival in the CABG-only cohort and enhance survival in the CABG�MVRep group with an intermediate outcome in those randomized to MED. Indeed, we noted more diabetes mellitus among the patients in whom surgeons decided not to treat the mitral valve. On the other hand, the risk at randomization index was similar in both groups. The patients subjected to MVRep had larger left ventricles on average and lower EFs. It appears that the main factor related to surgeon's decision was the region of the world where the patient was enrolled. Moreover, statistical adjustment for baseline characteristics of STICH patients actually accentuated the survival advantage of CABG�MVRep over CABG alone. Still, there are factors that could not be adjusted for in multivariable modeling. Information on surgical intraoperative decision making relative to MVRep was not collected, and the potential for confounding based on operative conduct exists. Although 40% of the CABG-only procedures were performed off pump, suggesting preoperative decisions against mitral valve surgery, intraoperative events cannot be excluded as a source of bias against CABG without MVRep.
